肝病指南中的成本与价值：2011-2022 年。
Cost and value in liver disease guidelines: 2011-2022.
机构信息
Division of Gastroenterology, Department of Medicine, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.
Department of Gastroenterology and Hepatology, New York Presbyterian, Weill Cornell Medicine, New York, New York, USA.
出版信息
Hepatol Commun. 2023 Jan 3;7(1):e0001. doi: 10.1097/HC9.0000000000000001. eCollection 2023 Jan 1.
BACKGROUND
Chronic liver disease (CLD) is associated with rising health care utilization and cost. We aimed to describe the frequency of cost/value (C/V) statements in CLD-related clinical guidance documents (CGDs).
METHODS
CGD with a focus on CLD published between January 2011 and February 2022 from 3 US societies [Association for the Study of Liver Diseases (AASLD), American College of Gastroenterology (ACG), and American Gastroenterological Association (AGA)] were analyzed.
FINDINGS
Forty-five CGDs were identified. Eighty of 1334 guidance statements were C/V statements (6%). Only 1.1% reported patient-level costs and none reported out-of-pocket costs. Despite the increased importance of incorporating cost and value into care, the proportion of C/V statements in CGDs related to liver disease is low.
背景
慢性肝病（CLD）与医疗保健利用率和成本的上升有关。我们旨在描述与 CLD 相关的临床指南文件（CGD）中成本/价值（C/V）声明的频率。
方法
分析了 2011 年 1 月至 2022 年 2 月期间，美国 3 个学会（肝脏病研究协会（AASLD）、美国胃肠病学会（ACG）和美国胃肠病协会（AGA））发布的重点为 CLD 的 45 篇 CGD。
结果
共确定了 45 篇 CGD。在 1334 条指导意见中有 80 条是 C/V 声明（6%）。仅报告了 1.1%的患者层面的成本，没有报告自付费用。尽管越来越重视将成本和价值纳入护理，但 CGD 中与肝病相关的 C/V 声明比例较低。
Zotero 插件